QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NASDAQ:ALNY

Alnylam Pharmaceuticals - ALNY Stock Forecast, Price & News

$224.14
-9.23 (-3.96%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$224.02
$234.70
50-Day Range
$204.79
$241.31
52-Week Range
$117.58
$242.97
Volume
697,445 shs
Average Volume
792,940 shs
Market Capitalization
$27.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$243.72

Alnylam Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.68 Rating Score
Upside/​Downside
8.7% Upside
$243.72 Price Target
Short Interest
Bearish
4.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.52
Upright™ Environmental Score
News Sentiment
0.68mentions of Alnylam Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$378,567 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($9.62) to ($6.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

Medical Sector

896th out of 1,027 stocks

Pharmaceutical Preparations Industry

438th out of 500 stocks

ALNY stock logo

About Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Stock News Headlines

Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Needham Keeps Their Buy Rating on Cidara Therapeutics (CDTX)
3 Growth Stocks That Could Rocket Higher in 2023
SVB Securities Reaffirms Their Hold Rating on Wave Life Sciences (WVE)
See More Headlines
Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Company Calendar

Last Earnings
10/27/2021
Today
2/06/2023
Next Earnings (Confirmed)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALNY
CUSIP
02043Q10
Employees
1,665
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$243.72
High Stock Price Forecast
$415.00
Low Stock Price Forecast
$143.00
Forecasted Upside/Downside
+8.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.68
Research Coverage
19 Analysts

Profitability

Net Income
$-852,820,000.00
Net Margins
-123.02%
Pretax Margin
-122.83%

Debt

Sales & Book Value

Annual Sales
$844.29 million
Book Value
$4.92 per share

Miscellaneous

Free Float
121,306,000
Market Cap
$27.58 billion
Optionable
Optionable
Beta
0.48

Social Links


Key Executives

  • Yvonne L. GreenstreetYvonne L. Greenstreet
    Chief Executive Officer & Director
  • Akshay K. VaishnawAkshay K. Vaishnaw
    President
  • Jeffrey V. Poulton
    Chief Financial Officer & Executive Vice President
  • Pushkal P. Garg
    Chief Medical Officer & EVP-Medical Affairs
  • James P. Bilotta
    Chief Information Officer & SVP













ALNY Stock - Frequently Asked Questions

Should I buy or sell Alnylam Pharmaceuticals stock right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALNY shares.
View ALNY analyst ratings
or view top-rated stocks.

What is Alnylam Pharmaceuticals' stock price forecast for 2023?

19 Wall Street research analysts have issued 12 month price objectives for Alnylam Pharmaceuticals' stock. Their ALNY share price forecasts range from $143.00 to $415.00. On average, they predict the company's share price to reach $243.72 in the next year. This suggests a possible upside of 8.2% from the stock's current price.
View analysts price targets for ALNY
or view top-rated stocks among Wall Street analysts.

How have ALNY shares performed in 2023?

Alnylam Pharmaceuticals' stock was trading at $237.65 at the start of the year. Since then, ALNY stock has decreased by 5.2% and is now trading at $225.22.
View the best growth stocks for 2023 here
.

Are investors shorting Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals saw a increase in short interest in January. As of January 15th, there was short interest totaling 5,680,000 shares, an increase of 11.2% from the December 31st total of 5,110,000 shares. Based on an average daily trading volume, of 783,400 shares, the short-interest ratio is currently 7.3 days.
View Alnylam Pharmaceuticals' Short Interest
.

When is Alnylam Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our ALNY earnings forecast
.

How can I listen to Alnylam Pharmaceuticals' earnings call?

Alnylam Pharmaceuticals will be holding an earnings conference call on Thursday, February 23rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its earnings results on Wednesday, October, 27th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing the consensus estimate of ($1.51) by $0.21. The biopharmaceutical company earned $187.63 million during the quarter, compared to analysts' expectations of $218.69 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 430.74% and a negative net margin of 123.02%. Alnylam Pharmaceuticals's revenue for the quarter was up 49.1% on a year-over-year basis. During the same period last year, the company posted ($2.18) earnings per share.

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (7.65%), Sumitomo Mitsui Trust Holdings Inc. (0.27%), New York State Common Retirement Fund (0.13%), Tobam (0.09%), DekaBank Deutsche Girozentrale (0.07%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Akshay Vaishnaw, Barry E Greene, Indrani Lall Franchini, Jeffrey W Dunn, John Maraganore, Laurie Keating, Phillip A Sharp, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends
.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $225.22.

How much money does Alnylam Pharmaceuticals make?

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $27.71 billion and generates $844.29 million in revenue each year. The biopharmaceutical company earns $-852,820,000.00 in net income (profit) each year or ($9.77) on an earnings per share basis.

How many employees does Alnylam Pharmaceuticals have?

The company employs 1,665 workers across the globe.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The official website for the company is www.alnylam.com. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101.

This page (NASDAQ:ALNY) was last updated on 2/6/2023 by MarketBeat.com Staff